CLYM Stock Analysis: Buy, Sell, or Hold?
CLYM - Climb Bio, Inc. Common Stock
$12.75
0.45 (3.66%)
▲
5d:
+19.05%
30d:
+15.91%
90d:
+90.87%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When CLYM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: CLYM is 7.8% above its trading range ($11.83). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: CLYM is 7.8% above its trading range ($11.83). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: CLYM is currently trading at $12.75, which is considered extended relative to its 30-day fair value range of $10.46 to $11.83.
Technical Outlook: Technically, CLYM is in a strong uptrend. The price is approaching resistance at $12.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: CLYM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.93 (+64.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CLYM is in a strong uptrend. The price is approaching resistance at $12.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: CLYM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.93 (+64.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.46 -
$11.83
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+7.8% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 64.1% below Wall St target ($20.93)
- CAUTION: Extended 7.8% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$10.46 -
$11.83
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$10.64
Resistance Level
$12.81
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.36
Wall Street Target
$20.93
(+64.1%)
Share & Embed Analysis
Last updated: June 24, 2026 9:43 PM ET
Data refreshes hourly during market hours. Next update: 10:43 PM
Data refreshes hourly during market hours. Next update: 10:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLYM showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ra Capital Management, L…
BUY
7111 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 59 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 60 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 61 BUY |
